Abstract Details

Title Dextromethorphan/Quinidine Attenuates Compulsive Shopping Behaviors and Pseudobulbar Affect in Individuals with Traumatic Brain Injury

Topic Neural Repair/Rehabilitation

Presentation(s) P04 - (-)

Poster/Presentation
Number 029

Objective

Background BACKGROUND: Pseudobulbar affect (PBA) comprises transient, involuntary paroxysms of affective lability resulting from various neurological conditions. Dextromethorphan/quinidine (DMQ) has been shown to effectively suppress PBA in diverse neurological populations.

Design/Methods DESIGN/METHODS: The medical records of 12 patients with traumatic brain injury (TBI) were examined following the clinical observations of one of the authors (JLF). All 12 patients had a stable history of PBA and frequently displayed impulsive behaviors post-TBI. Treatment with DMQ was indicated in all 12 patients for paroxysmal outbursts of laughing and crying classically associated with PBA.

Results RESULTS: The results of this case-series highlight DMQ as a potent pharmacotherapy for various neuropsychiatric behaviors secondary to TBI, including PBA. Treatment of PBA with DMQ in all 12 patients had the unexpected, salubrious benefit of decreasing the frequency of compulsive shopping behaviors.

Conclusions CONCLUSIONS: DMQ deserves consideration for the management of various neuropsychiatric behaviors associated with TBI, including PBA and impulsivity. Initiation of DMQ therapy holds the promise to significantly enhance the quality of life for individuals with PBA and poor impulse control. The co-occurring inhibition of compulsive shopping behaviors in this sample further supports a recently suggested hypothesis that the operational definition of PBA secondary to TBI be expanded to formally acknowledge the primary impairment of impulse control within which these episodes of affective lability frequently occur.

Authors/Disclosures
Christine M. Zakrzewski PRESENTER	No disclosure on file
Philip Defina, PhD (Internationl Brain Research Foundation, Inc.)	No disclosure on file
Jonathan L. Fellus, MD (Advanced Neurocare)	No disclosure on file
Silvia Tenembaum, MD	Dr. Tenembaum has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech-Roche Inc. . Dr. Tenembaum has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech-Roche Inc. . Dr. Tenembaum has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals Inc. .
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.

��ɫ��

��ɫ��